Form 4: Altimmune Director Plans 12,500 Share Purchase

Altimmune, Inc. Director Jerome Benedict Durso plans to purchase 12,500 shares of common stock on December 22, 2025, at a weighted average price of $4.1255.

Summary

• Jerome Benedict Durso, a Director of Altimmune, Inc. (ALT), plans to acquire 12,500 shares of the company's common stock.
• The transaction is scheduled for December 22, 2025.
• The shares are to be purchased at a weighted average price of $4.1255 per share.
• The purchase price range for these shares is from $4.1200 to $4.1300, inclusive.
• Following this planned transaction, Mr. Durso will beneficially own 12,500 shares directly.

Sentiment

Score: 8

Explanation: The planned purchase by a director signals strong confidence in the company's future, which is generally viewed very positively by the market, suggesting potential upside.

Positives

• A planned purchase of common stock by a company director signals strong internal confidence in Altimmune, Inc.'s future prospects and current valuation.
• The director's willingness to invest personal capital at the stated price range suggests a belief that the stock is undervalued or poised for growth.

Future Outlook

Director Jerome Benedict Durso plans to acquire 12,500 shares of Altimmune common stock on December 22, 2025, indicating a positive outlook on the company's future valuation and performance.

Industry Context

A planned insider purchase, particularly by a director, is often interpreted by the market as a strong vote of confidence in the company's strategic direction and future financial health. This can positively influence investor sentiment and potentially attract further investment, especially in the biotechnology sector where future pipeline success is critical.

Related Party Transactions

• Director Jerome Benedict Durso plans to purchase 12,500 shares of Altimmune, Inc. common stock on 12/22/2025, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders may interpret the planned insider purchase as a positive indicator of future company performance and value, potentially increasing investor confidence.
• The transaction could signal to potential investors that the company's leadership believes in its long-term prospects.

Next Steps

• The planned purchase of 12,500 shares by Director Jerome Benedict Durso is scheduled for December 22, 2025.

Key Dates

Recommendation

The planned acquisition of a significant block of shares by a director strongly suggests internal conviction in Altimmune's future prospects and current valuation. This insider buying activity, even if scheduled for a future date, is a compelling signal for potential investors, indicating management's belief in the company's upside potential.

Keywords

Altimmune, ALT, Insider Buy, Director Purchase, Form 4, Planned Transaction, Common Stock